| pubmed-article:9512391 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9512391 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:9512391 | lifeskim:mentions | umls-concept:C0004461 | lld:lifeskim |
| pubmed-article:9512391 | lifeskim:mentions | umls-concept:C0175173 | lld:lifeskim |
| pubmed-article:9512391 | lifeskim:mentions | umls-concept:C2327682 | lld:lifeskim |
| pubmed-article:9512391 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:9512391 | pubmed:dateCreated | 1998-4-29 | lld:pubmed |
| pubmed-article:9512391 | pubmed:abstractText | We have examined the pattern of immunostaining for the high-affinity GABA transporter GAT-1 in the human temporal neocortex. Immunocytochemistry for GAT-1 labels terminal-like puncta in the neuropil and around unstained cell bodies. The characteristic terminal portions of chandelier cell axons (Ch-terminals, which form multiple inhibitory GABAergic synaptic contacts with the axon initial segments of pyramidal cells) were among the strongest immunocytochemically stained elements for GAT-1. Since Ch-terminals are immunoreactive for the calcium-binding protein parvalbumin, experiments were carried out to study the co-localization of GAT-1 and parvalbumin in Ch-terminals. These experiments showed that the vast majority of Ch-terminals immunoreactive for GAT-1 were also immunoreactive for PV. We concluded that GAT-1 transporter may have an important functional role in controlling pyramidal cell activity. | lld:pubmed |
| pubmed-article:9512391 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9512391 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9512391 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9512391 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9512391 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9512391 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9512391 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9512391 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9512391 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9512391 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9512391 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9512391 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9512391 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:9512391 | pubmed:issn | 0959-4965 | lld:pubmed |
| pubmed-article:9512391 | pubmed:author | pubmed-author:DeFelipeJJ | lld:pubmed |
| pubmed-article:9512391 | pubmed:author | pubmed-author:González-Albo... | lld:pubmed |
| pubmed-article:9512391 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9512391 | pubmed:day | 16 | lld:pubmed |
| pubmed-article:9512391 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:9512391 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9512391 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9512391 | pubmed:pagination | 467-70 | lld:pubmed |
| pubmed-article:9512391 | pubmed:dateRevised | 2006-11-20 | lld:pubmed |
| pubmed-article:9512391 | pubmed:meshHeading | pubmed-meshheading:9512391-... | lld:pubmed |
| pubmed-article:9512391 | pubmed:meshHeading | pubmed-meshheading:9512391-... | lld:pubmed |
| pubmed-article:9512391 | pubmed:meshHeading | pubmed-meshheading:9512391-... | lld:pubmed |
| pubmed-article:9512391 | pubmed:meshHeading | pubmed-meshheading:9512391-... | lld:pubmed |
| pubmed-article:9512391 | pubmed:meshHeading | pubmed-meshheading:9512391-... | lld:pubmed |
| pubmed-article:9512391 | pubmed:meshHeading | pubmed-meshheading:9512391-... | lld:pubmed |
| pubmed-article:9512391 | pubmed:meshHeading | pubmed-meshheading:9512391-... | lld:pubmed |
| pubmed-article:9512391 | pubmed:meshHeading | pubmed-meshheading:9512391-... | lld:pubmed |
| pubmed-article:9512391 | pubmed:meshHeading | pubmed-meshheading:9512391-... | lld:pubmed |
| pubmed-article:9512391 | pubmed:meshHeading | pubmed-meshheading:9512391-... | lld:pubmed |
| pubmed-article:9512391 | pubmed:meshHeading | pubmed-meshheading:9512391-... | lld:pubmed |
| pubmed-article:9512391 | pubmed:meshHeading | pubmed-meshheading:9512391-... | lld:pubmed |
| pubmed-article:9512391 | pubmed:meshHeading | pubmed-meshheading:9512391-... | lld:pubmed |
| pubmed-article:9512391 | pubmed:meshHeading | pubmed-meshheading:9512391-... | lld:pubmed |
| pubmed-article:9512391 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9512391 | pubmed:articleTitle | Chandelier cell axons are immunoreactive for GAT-1 in the human neocortex. | lld:pubmed |
| pubmed-article:9512391 | pubmed:affiliation | Instituto Cajal, CSIC, Madrid, Spain. | lld:pubmed |
| pubmed-article:9512391 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9512391 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:6529 | entrezgene:pubmed | pubmed-article:9512391 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9512391 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9512391 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9512391 | lld:pubmed |
